Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol)

Introduction Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting drug use as the main risk factor among the estimated 200 000 people currently infected. Despite effective prevention interventions, chronic HCV prevalence remains around 40% among people...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Jeremy Horwood, Andrew Radley, John F Dillon, Peter Vickerman, Rory N Gunson, Mary Ramsay, Chris Metcalfe, William Hollingworth, Hannah Fraser, Helen Harris, Ellen Heinsbroek, Lawrie Elliott, Paul Flowers, Sema Mandal, Matthew Hickman, David Goldberg, Natasha Martin, Emma Hamilton, Daniela De Angelis, Graham Foster, Peter Donnan, Ann Eriksen, Samreen Ijaz, David Liddell, Lewis J Z Beer, Kate Drysdale, Rachel Glass, Lesley Graham, Ross Harris, Vivian Hope, Sarah Karen Inglis, Hamish Innes, Athene Lane, Jade Meadows, Andrew McAuley, Stephanie Migchelsen, Alex Murray, Gareth Myring, Norah E Palmateer, Anne Presanis, Pantelis Samartsidis, Ruth Simmons, Katy Sinka, Gabriele Vojt, Zoe Ward, David Whiteley, Alan Yeung, Sharon J Hutchinson
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMJ Publishing Group 2019-09-01
Rangatū:	BMJ Open
Urunga tuihono:	https://bmjopen.bmj.com/content/9/9/e029538.full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!